Inotiv Secures Short-Term Waiver on Credit Agreement Liquidity

Inotiv ( (NOTV) ) has provided an update.

On May 4, 2026, Inotiv, Inc. obtained from its lenders a waiver of the minimum liquidity covenant under its existing Credit Agreement, which originally dates back to November 5, 2021 and governs financing arrangements with certain subsidiaries and lending parties. The waiver applied only to the minimum liquidity requirements for the May 1 and May 8, 2026 test dates, leaving all other terms of the Credit Agreement unchanged and signaling targeted, short-term relief rather than a broader restructuring of the company’s debt facilities.

The most recent analyst rating on (NOTV) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Inotiv stock, see the NOTV Stock Forecast page.

Spark’s Take on NOTV Stock

According to Spark, TipRanks’ AI Analyst, NOTV is a Neutral.

The score is held down primarily by weak financial quality—persistent losses, negative operating/free cash flow, and high leverage that elevates liquidity/refinancing risk. Technicals remain weak with price below key longer-term averages and negative MACD. Offsetting factors include improving DSA commercial momentum (awards, backlog, margin gains), but lack of formal guidance and RMS volume pressure limit confidence in a near-term turnaround.

To see Spark’s full report on NOTV stock, click here.

More about Inotiv

Inotiv, Inc. operates in the life sciences and pharmaceutical research services industry, providing nonclinical and analytical contract research services that support drug discovery and development for biopharmaceutical and related clients. The company focuses on supplying specialized scientific expertise and testing capabilities to advance preclinical research programs.

Average Trading Volume: 711,253

Technical Sentiment Signal: Sell

Current Market Cap: $10.39M

For detailed information about NOTV stock, go to TipRanks’ Stock Analysis page.